{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-083410","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.746943+00:00","generated_at":"2026-06-24T07:43:28.811615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck Q2 revenue up 28% to $14.6B; non-GAAP EPS $1.87 vs $0.61; raises 2022 sales guidance","bullets":["KEYTRUDA sales rose 26% to $5.3B; GARDASIL/GARDASIL 9 up 36% to $1.7B, driven by China demand.","LAGEVRIO contributed $1.2B in Q2 sales; full-year outlook maintained at $5.0-$5.5B.","GAAP EPS $1.55 vs $0.48; non-GAAP EPS $1.87 vs $0.61, reflecting strong operational performance.","Company raised and narrowed 2022 full-year sales guidance to $57.5-$58.5B (18-20% growth).","Non-GAAP EPS guidance narrowed to $7.25-$7.35; includes ~$0.09 impact from Orion upfront payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-083410","json":"https://secwatch.observer/filing/0001104659-22-083410.json","markdown":"https://secwatch.observer/filing/0001104659-22-083410.md","text":"https://secwatch.observer/filing/0001104659-22-083410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465922083410/0001104659-22-083410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465922083410/tm2221828d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:43:28.811615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}